The good health news that could improve your life in 2026
This is Everyday Science with Clare Wilson, a subscriber-only newsletter from The i Paper. If you’d like to get this direct to your inbox every week, you can sign up here. Hello, and welcome back to Everyday Science. Are you in a post-Christmas slump? If so, lift your spirits by reading some good news, the progress that has been […]
Twenty Twenty-Five
2025 was… a year. And I made it to the end of that year. If you’re reading this, I imagine you did too and let’s celebrate that. But also not one without loss; of loved ones, of health, of relationships, of jobs, of liberties, of pursuits of happiness. Let’s mourn those. My year was mundane […]
What’s ahead for the weight-loss drugs known as GLP-1s in 2026 – NPR
What’s ahead for the weight-loss drugs known as GLP-1s in 2026 NPR 2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit CNBC What to watch for in weight loss drugs in 2026: Price changes, GLP-1 pills and more NBC News The weight-loss drugs on trial in 2026 may trump […]
How To Microdose GLP-1 (& How To Make Eating Less EASY Even After You Stop Your Peptides) With Geoff Cook of Noom
What I Discuss with Geoff Cook: How Noom helps people feel better today and live longer by focusing on mindset, vitality, and the use of very small GLP-1 microdoses to quiet food noise without extreme dieting or appetite loss…03:31 Why Noom chooses semaglutide for microdosing, how FDA-regulated compounding ensures safety and […] The post How […]
The bio-pirate’s guide to GLP-1 agonists
Published on January 2, 2026 3:32 AM GMT How to lose weight, infringe patents, and possibly poison yourself for 22 Euros a month. Introduction In March 2025, Scott Alexander wrote: Others are turning amateur chemist. You can order GLP-1 peptides from China for cheap. Once you have the peptide, all you have to do is […]
Obesity drugs may spur licensing, distribution deals for Indian drugmakers after patent expires
The rising demand for obesity drugs is prompting Indian pharma firms to pursue licensing and distribution partnerships, particularly for GLP-1 drugs. Major deals have been signed, with analysts predicting continued growth in the market as patents expire and supply chain collaborations emerge.
Older Americans are quitting GLP-1 weight-loss drugs for 4 key reasons – Fox News
Older Americans are quitting GLP-1 weight-loss drugs for 4 key reasons Fox News
Media mogul, Oprah Winfrey reveals unexpected changes after using weight loss drugs
Media mogul Oprah Winfrey has opened up about the unexpected effects she experienced after using GLP-1 weight loss medications, a class of drugs that includes Ozempic, Wegovy and Mounjaro. According to Daily Mail, Winfrey, 71, first disclosed in December 2023 that she had started using a GLP-1 drug as a maintenance tool alongside diet and exercise. […]
Viking Therapeutics: A Wide-Open Oral GLP-1 Market
Older Americans are quitting GLP-1 weight-loss drugs for 4 key reasons
GLP-1 medications have dominated the weight-loss landscape this year — but some older Americans are reportedly kicking the trend to the curb. A study published in JAMA in January 2025 — which looked at more than 125,000 overweight or obese people — found that nearly 47% of those with type 2 diabetes and 65% of […]